The Desmoid Tumor Research Foundation

October 2020

A Timely Oral Option: Single Agent Vinorelbine in Desmoid Tumours

Author Information

Gennatas S(1), Chamberlain F, Smrke A(1), Stewart J(1,2), Hayes A(1,2), Roden L(1), Messiou C(1,2), Kowa JY(1,3), Estival A(4), Chauhan D(1), Thway K(1,2), Fisher C(5), van der Graaf W(1,2,6), Jones RL(1,2), Benson C(1).

(1)The Royal Marsden NHS Foundation Trust. (2)Institute of Cancer Research, London, UK. (3)St George's Hospitals NHS Trust, London, UK. (4)Catalan Institute of Oncology, Barcelona, Spain. (5)Univ Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. (6)Netherlands Cancer Institute, Amsterdam, Netherlands.

Publication

Oncologist

Summary

The aim of this study was to evaluate the efficacy and safety of treatment of desmoid tumours (DT) with single agent oral vinorelbine. A retrospective review of patients treated with vinorelbine 90mg orally on Days 1, 8 and 15 of a 28-day cycle from January 2004-July 2019 was performed. Response was assessed using Response Evaluation Criteria in Solid Tumours version 1.1. 29 patients were included. Response rate was 20.7% (6/29) and clinical benefit rate (response by RECIST 1.1 and/or clinical symptom improvement) was 65.5% (19/29). No patient experienced grade 3 or above toxicity. Common toxicities were grade 1-2 nausea (14/26, 48.3%), fatigue (9/26, 31.0%) and diarrhea (4/26, 13.8%). Single agent oral vinorelbine is an effective, safe and well tolerated treatment for DT.

View Abstract